No association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumab
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
No association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumab
Authors
Keywords
Cognitive impairment, Statins, Alzheimer's disease, Memory, Cholesterol, Medical risk factors, Cardiovascular therapy, Neuropsychological testing
Journal
PLoS One
Volume 17, Issue 4, Pages e0266615
Publisher
Public Library of Science (PLoS)
Online
2022-04-12
DOI
10.1371/journal.pone.0266615
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- HMGB1/RAGE/TLR4 axis and glutamate as novel targets for PCSK9 inhibitor in high fat cholesterol diet induced cognitive impairment and amyloidosis
- (2021) Sally A. Abuelezz et al. LIFE SCIENCES
- Cognition After Lowering LDL-Cholesterol With Evolocumab
- (2020) Baris Gencer et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders
- (2020) Emma M. O’Connell et al. Frontiers in Neuroscience
- Proprotein Convertase Subtilisin/Kexin Type 9, Brain Cholesterol Homeostasis and Potential Implication for Alzheimer’s Disease
- (2019) Maria Pia Adorni et al. Frontiers in Aging Neuroscience
- Proprotein convertase subtilisin/kexin type 9 (PCSK9) in Alzheimer’s disease: A genetic and proteomic multi-cohort study
- (2019) Cynthia Picard et al. PLoS One
- Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
- (2017) Robert P Giugliano et al. LANCET
- Cognitive Function in a Randomized Trial of Evolocumab
- (2017) Robert P. Giugliano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer’s disease
- (2017) Nophar Geifman et al. Alzheimers Research & Therapy
- Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial
- (2016) Marc S. Sabatine et al. AMERICAN HEART JOURNAL
- Increased PCSK9 Cerebrospinal Fluid Concentrations in Alzheimer’s Disease
- (2016) Francesca Zimetti et al. JOURNAL OF ALZHEIMERS DISEASE
- Hyperlipidemia-induced apoptosis of hippocampal neurons in apoE(−/−) mice may be associated with increased PCSK9 expression
- (2016) Xue-Shan Zhao et al. Molecular Medicine Reports
- Early neurological and cognitive impairments in subclinical cerebrovascular disease
- (2016) PenkaA Atanassova et al. NEUROLOGY INDIA
- Do Statins Impair Cognition? A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- (2015) Brian R. Ott et al. JOURNAL OF GENERAL INTERNAL MEDICINE
- APOE ε4 Genotype and the Risk for Subjective Cognitive Impairment in Elderly Persons
- (2015) Janina Krell-Roesch et al. JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES
- Statins and Cognitive Function
- (2013) Karl Richardson et al. ANNALS OF INTERNAL MEDICINE
- Cardiac disease and cognitive impairment: a systematic review
- (2012) Laura H P Eggermont et al. HEART
- The measurement of everyday cognition: Development and validation of a short form of the Everyday Cognition scales
- (2011) Sarah Tomaszewski Farias et al. Alzheimers & Dementia
- Human apoE Isoforms Differentially Regulate Brain Amyloid- Peptide Clearance
- (2011) J. M. Castellano et al. Science Translational Medicine
- APOEpredicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging
- (2009) John C. Morris et al. ANNALS OF NEUROLOGY
- The effects of apolipoprotein E on non-impaired cognitive functioning: A meta-analysis
- (2009) Nick M. Wisdom et al. NEUROBIOLOGY OF AGING
- Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease
- (2009) A. Drzezga et al. NEUROLOGY
- The measurement of everyday cognition (ECog): Scale development and psychometric properties.
- (2008) Sarah Tomaszewski Farias et al. NEUROPSYCHOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started